

**TOXICOLOGICAL PROFILE FOR
CHLORODIBENZOFURANS**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

May 1994

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The revised list of the 275 most hazardous substances was published in the Federal Register on October 28, 1992 (57 FR 48801). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166).

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to succinctly characterize the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

Foreword

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTRIBUTORS

CHEMICAL MANAGERS(S)/AUTHOR(S):

Hana Pohl, M.D., Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Stephen Bosch, B.S.

Syracuse Research Corporation, Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Green Border Review. Green Border review assures the consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying endpoints.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

PEER REVIEW

A peer review panel was assembled for CDFs. The panel consisted of the following members:

1. Dr. Judith Bellin, Private Consultant, Washington, DC
2. Dr. Shane Que Hee, Department of Environmental Health Sciences, UCLA School of Public Health, Los Angeles, California
3. Dr. Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas
4. Dr. Arnold Schecter, College of Medicine, Clinical Campus, Health Science Center/Syracuse, State University of New York, Binghamton, New York.

These experts collectively have knowledge of the CDFs' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
CONTRIBUTORS	vii
PEER REVIEW	ix
LIST OF FIGURES	xv
LIST OF TABLES	xvii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT ARE CDFs?	1
1.2 WHAT HAPPENS TO CDFs WHEN THEY ENTER THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO CDFs?	3
1.4 HOW CAN CDFs ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN CDFs AFFECT MY HEALTH?	5
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO CDFs?	7
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	7
1.8 WHERE CAN I GET MORE INFORMATION?	8
2. HEALTH EFFECTS	9
2.1 INTRODUCTION	9
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	9
2.2.1 Inhalation Exposure	11
2.2.1.1 Death	11
2.2.1.2 Systemic Effects	11
2.2.1.3 Immunological Effects	11
2.2.1.4 Neurological Effects	11
2.2.1.5 Reproductive Effects	11
2.2.1.6 Developmental Effects	11
2.2.1.7 Genotoxic Effects	11
2.2.1.8 Cancer	11
2.2.2 Oral Exposure	12
2.2.2.1 Death	13
2.2.2.2 Systemic Effects	14
2.2.2.3 Immunological Effects	39
2.2.2.4 Neurological Effects	41
2.2.2.5 Reproductive Effects	42
2.2.2.6 Developmental Effects	43
2.2.2.7 Genotoxic Effects	45
2.2.2.8 Cancer	45

2.2.3	Dermal Exposure	46
2.2.3.1	Death	46
2.2.3.2	Systemic Effects	46
2.2.3.3	Immunological Effects	50
2.2.3.4	Neurological Effects	51
2.2.3.5	Reproductive Effects	51
2.2.3.7	Genotoxic Effects	51
2.3	TOXICOKINETICS	52
2.3.1	Absorption	53
2.3.1.1	Inhalation Exposure	53
2.3.1.2	Oral Exposure	53
2.3.1.3	Dermal Exposure	54
2.3.2	Distribution	55
2.3.2.1	Inhalation Exposure	56
2.3.2.2	Oral Exposure	56
2.3.2.3	Dermal Exposure	58
2.3.2.4	Other Routes of Exposure	59
2.3.3	Metabolism	60
2.3.4	Excretion	62
2.3.4.1	Inhalation Exposure	62
2.3.4.2	Oral Exposure	62
2.3.4.3	Dermal Exposure	64
2.3.4.4	Other Routes of Exposure	65
2.3.5	Mechanism of Action	66
2.4	RELEVANCE TO PUBLIC HEALTH	69
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	90
2.5.1	Biomarkers Used to Identify or Quantify Exposure to CDFs	91
2.5.2	Biomarkers Used to Characterize Effects Caused by CDFs	92
2.6	INTERACTIONS WITH OTHER SUBSTANCES	93
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	95
2.8	METHODS FOR REDUCING TOXIC EFFECTS	96
2.8.1	Reducing Peak Absorption Following Exposure	96
2.8.2	Reducing Body Burden	96
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	97
2.9	ADEQUACY OF THE DATABASE	98
2.9.1	Existing Information on Health Effects of CDFs	98
2.9.2	Identification of Data Needs	100
2.9.3	On-going Studies	109
3.	CHEMICAL AND PHYSICAL INFORMATION	111
3.1	CHEMICAL IDENTITY	111
3.2	PHYSICAL AND CHEMICAL PROPERTIES	111
4.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	121
4.1	PRODUCTION	121
4.2	IMPORT/EXPORT	122
4.3	USE	122
4.4	DISPOSAL	122

5. POTENTIAL FOR HUMAN EXPOSURE	125
5.1 OVERVIEW	125
5.2 RELEASES TO THE ENVIRONMENT	128
5.2.1 Air	136
5.2.2 Water	136
5.2.3 Soil	137
5.3 ENVIRONMENTAL FATE	137
5.3.1 Transport and Partitioning	138
5.3.2 Transformation and Degradation	142
5.3.2.1 Air	142
5.3.2.2 Water	142
5.3.2.3 Sediment and Soil	143
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	144
5.4.1 Air	144
5.4.2 Water	149
5.4.3 Sediment and Soil	151
5.4.4 Other Environmental Media	152
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	157
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	164
5.7 ADEQUACY OF THE DATABASE	164
5.7.1 Identification of Data Needs	165
5.7.2 On-going Studies	167
6. ANALYTICAL METHODS	169
6.1 BIOLOGICAL MATERIALS	169
6.2 ENVIRONMENTAL SAMPLES	174
6.3 ADEQUACY OF THE DATABASE	180
6.3.1 Identification of Data Needs	181
6.3.2 On-going Studies	181
7. REGULATIONS AND ADVISORIES	183
8. REFERENCES	185
9. GLOSSARY	223
APPENDICES	
A. USER'S GUIDE	A-1
B. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	B-1

LIST OF FIGURES

2-1 Levels of Significant Exposure to CDFs - Oral	25
2-2 Existing Information on Health Effects of CDFs	99
5-1 Frequency of NPL Sites with CDF Contamination	126

LIST OF TABLES

2-1	Levels of Significant Exposure to CDFs - Oral	15
2-2	Levels of Significant Exposure to CDFs - Dermal	47
2-3	Recommended Toxicity Equivalency Factors (TEFs) for CDFs and CDDs	73
3-1	Chemical Identities of CDFs	112
3-2	Physical and Chemical Properties of CDFs	117
5-1	Levels of CDFs in Commercial Chlorinated Phenols ($\mu\text{g/g}$)	132
5-2	Levels of CDFs in Commercial PCBs ($\mu\text{g/g}$)	134
5-3	Concentrations of CDFs in Ambient Indoor and Outdoor Air in North America	145
5-4	Levels of CDFs in Fish and Other Aquatic Organisms	153
5-5	Levels of CDFs in Human Adipose Tissue	160
5-6	Levels of CDFs in Human Milk	162
5-7	Mean Levels of CDFs in Human Whole Blood (ppt Lipid) From Various Countries	163
6-1	Analytical Methods for Determining CDFs in Biological Materials	170
6-2	Analytical Methods for Determining CDFs in Environmental Samples	175

